Skip to main content
SpringerLink
Log in

Catapulting clopidogrel pharmacogenomics forward

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

The antiplatelet drug clopidogrel helps prevent stent-associated thrombosis, but the antiplatelet effects are quite variable and the clinical consequences can be serious. New findings show that the variability in clopidogrel efficacy is affected by the enzyme paraoxonase-1 (PON1), which is required for clopidogrel bioactivation (pages 110–116).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: There are two major steps in the metabolism of clopidogrel.

Marina Corral

References

  1. Topol, E.J. Textbook of Interventional Cardiology. 5th edn. Ch. 66, 1221–1240 (Elsevier, Philadelphia, 2008).

    Google Scholar 

  2. Winslow, R. Plavix rival gains from studies. Wall Street Journal (30 August 2010).

    Google Scholar 

  3. Serebruany, V.L. et al. J. Am. Coll. Cardiol. 45, 246–251 (2005).

    Article  CAS  Google Scholar 

  4. Mauri, L. et al. N. Engl. J. Med. 356, 1020–1029 (2007).

    Article  CAS  Google Scholar 

  5. Bouman, H.J. et al. Nat. Med. 17, 110–116 (2011).

    Article  CAS  Google Scholar 

  6. Hulot, J.S. et al. Blood 108, 2244–2247 (2006).

    Article  CAS  Google Scholar 

  7. Simon, T. et al. N. Engl. J. Med. 360, 363–375 (2009).

    Article  CAS  Google Scholar 

  8. Collet, J.P. et al. Lancet 373, 309–317 (2009).

    Article  CAS  Google Scholar 

  9. Mega, J.L. et al. N. Engl. J. Med. 360, 354–362 (2009).

    Article  CAS  Google Scholar 

  10. Hulot, J.S. et al. J. Am. Coll. Cardiol. 56, 134–143 (2010).

    Article  CAS  Google Scholar 

  11. Mega, J.L. et al. J. Am. Med. Assoc. 304, 1821–1830 (2010).

    Article  CAS  Google Scholar 

  12. Shuldiner, A.R. et al. J. Am. Med. Assoc. 302, 849–857 (2009).

    Article  CAS  Google Scholar 

  13. Damani, S.B. & Topol, E.J. J. Am. Coll. Cardiol. 56, 109–111 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Eric J. Topol and Nicholas J. Schork are at the Scripps Translational Science Institute, the Scripps Research Institute, Scripps Genomic Medicine and Scripps Health, La Jolla, California, USA.,

    Eric J Topol & Nicholas J Schork

  2. Eric J. Topol is also at the Scripps Clinic, La Jolla, California, USA.,

    Eric J Topol

Authors
  1. Eric J Topol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J Schork
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J Topol.

Ethics declarations

Competing interests

E.J.T. is a consultant/advisor to Sanofi-Aventis, Daiichi and Quest Diagnostics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Topol, E., Schork, N. Catapulting clopidogrel pharmacogenomics forward. Nat Med 17, 40–41 (2011). https://doi.org/10.1038/nm0111-40

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0111-40

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation